Product News

Hetlioz for Non-24-Hour Disorder Now Available

Published on

Vanda Pharmaceuticals Inc this week announced the availability of Hetlioz. Hetlioz is the first treatment approved by the US Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a chronic circadian rhythm disorder that affects up to 70% of people who are totally blind.

Vanda has launched HetliozSolutions to support and facilitate the treatment of totally blind people living with Non-24. HetliozSolutions will provide patients with a host of resources including information about Non-24 and Hetlioz, insurance support, overview of financial assistance programs, and pharmacy access.

“The availability of Hetlioz marks a major milestone for totally blind people who have been without an approved, safe, and effective treatment for Non-24. We are also excited to bring a broad range of services to patients through HetliozSolutions,” says Mihael H. Polymeropoulos, MD, Vanda’s president and CEO, in a release.

Hetlioz, which was approved by the FDA in January 2014, is available through specialty pharmacies in the United States.